Anhui Huaheng Biotechnology Co., Ltd. (SHA:688639)
China · Delayed Price · Currency is CNY 29.10
+0.40 (1.39%)
Apr 21, 2026, 3:00 PM CST
SHA:688639 Revenue
In the year 2025, Anhui Huaheng Biotechnology had annual revenue of 2.86B CNY with 31.40% growth. Anhui Huaheng Biotechnology had revenue of 668.30M in the quarter ending December 31, 2025, with 4.60% growth.
Revenue
2.86B
Revenue Growth
+31.40%
P/S Ratio
2.50
Revenue / Employee
1.27M
Employees
2,252
Market Cap
7.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 683.90M | 31.40% |
| Dec 31, 2024 | 2.18B | 239.67M | 12.37% |
| Dec 31, 2023 | 1.94B | 519.62M | 36.63% |
| Dec 31, 2022 | 1.42B | 464.56M | 48.69% |
| Dec 31, 2021 | 954.10M | 466.85M | 95.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.17B |
| Kexing Biopharm | 1.54B |
| Xiangxue Pharmaceutical | 1.47B |
| Nanjing Vazyme Biotech | 1.38B |
| Chengdu Kanghua Biological Products | 1.21B |
| Wuhan Keqian Biology Co.,Ltd | 949.74M |
| R&G PharmaStudies | 851.01M |
| GemPharmatech | 793.25M |